Tuesday - March 24, 2026
GSK's B7-H3-Targeted Antibody-Drug Conjugate, Risvutatug Rezetecan, Granted Orphan Drug Designation for Small-Cell Lung Cancer in Japan
March 24, 2026
LONDON, England, March 24 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on March 23, 2026:

* * *

GSK's B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, granted Orphan Drug Designation for small-cell lung cancer in Japan

* Designation supported by early clinical data showing durable responses in certain types of small-cell lung cancer (SCLC)

* Extensive-stage SCLC is associate . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products